Naked Antibody Treatment Set to Revolutionize Cancer Care - Major Breakthrough Confirmed!

LONDON and MONTREAL, Oct. 24, 2024 /PRNewswire/ -- Cancer Research UK, one of the world's largest funders of cancer research, and KisoJi Biotechnology Inc., a company focussed on the discovery and development of antibody therapeutics, have signed a landmark agreement that will see them collaborate to advance the first naked antibody against TROP2 into the clinic. This groundbreaking partnership is set to revolutionize cancer care and bring new hope to millions of people worldwide.

The collaboration will focus on developing a new treatment that uses a naked antibody to target TROP2, a protein that is found on the surface of many cancer cells. TROP2 is overexpressed in a wide range of cancers, including breast, lung, colon, and prostate cancer, making it an attractive target for cancer therapy.

The antibody, which has been designed and developed by KisoJi Biotechnology, has shown significant promise in preclinical trials, demonstrating its ability to selectively target and kill cancer cells while leaving healthy cells intact. With the support of Cancer Research UK, the partners will now work together to take the antibody into clinical trials, where it will be tested for its safety and effectiveness in patients.

Cancer Research UK's involvement in the partnership is a significant boost to the development of this new treatment. As one of the world's largest funders of cancer research, the organization brings a wealth of expertise and resources to the table, including access to world-class research facilities and a network of leading cancer experts.

'We are thrilled to be partnering with KisoJi Biotechnology to advance this groundbreaking new treatment into the clinic,' said Dr. Iain Foulkes, Executive Director of Research and Innovation at Cancer Research UK. 'The development of naked antibodies against TROP2 has the potential to revolutionize the way we treat cancer, and we are committed to supporting this important work.'

'We are proud to be collaborating with Cancer Research UK, a world-renowned leader in cancer research,' added Dr. Kenji Ai, CEO of KisoJi Biotechnology. 'With their support, we are confident that we can bring this exciting new treatment to patients and make a real difference in the fight against cancer.'

The partnership between Cancer Research UK and KisoJi Biotechnology is a significant step forward in the development of new cancer treatments, and offers new hope to patients and families affected by this devastating disease.